3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Sell
32
PL Quote, Financials, Valuation and Earnings
Last price:
$3.44
Seasonality move
:
-13.41%
Day range:
$3.22 - $3.42
52-week range:
$1.67 - $6.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.04x
P/B ratio:
2.32x
Volume:
3.7M
Avg. volume:
4.8M
1-year change:
32.55%
Market cap:
$1B
Revenue:
$244.4M
EPS (TTM):
-$0.42
Analysts' Opinion
-
Consensus RatingPlanet Labs PBC has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.03, Planet Labs PBC has an estimated upside of 78.32% from its current price of $3.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.50 representing 100% downside risk from its current price of $3.38.
Fair Value
-
According to the consensus of 8 analysts, Planet Labs PBC has 78.32% upside to fair value with a price target of $6.03 per share.
PL vs. S&P 500
-
Over the past 5 trading days, Planet Labs PBC has underperformed the S&P 500 by -13.99% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Planet Labs PBC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Planet Labs PBC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Planet Labs PBC reported revenues of $61.6M.
Earnings Growth
-
Planet Labs PBC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Planet Labs PBC reported earnings per share of -$0.12.
Enterprise value:
799.5M
EV / Invested capital:
1.81x
Price / LTM sales:
4.04x
EV / EBIT:
--
EV / Revenue:
3.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$139.7M
Return On Assets:
-18.67%
Net Income Margin (TTM):
-50.42%
Return On Equity:
-25.69%
Return On Invested Capital:
-25.69%
Operating Margin:
-31.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $191.3M | $220.7M | $244.4M | $58.9M | $61.6M | |
| Gross Profit | $94M | $113M | $139.7M | $32.5M | $38.2M | |
| Operating Income | -$175.7M | -$169.7M | -$116.1M | -$33.9M | -$19.4M | |
| EBITDA | -$132.3M | -$122.1M | -$70.5M | -$22.3M | -$10.1M | |
| Diluted EPS | -$0.61 | -$0.51 | -$0.42 | -$0.11 | -$0.12 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $125.4M | $551.5M | $475.7M | $370.2M | $302.2M | |
| Total Assets | $399.3M | $821.4M | $752.7M | $702M | $633.8M | |
| Current Liabilities | $108.8M | $132M | $122.3M | $136.6M | $142.1M | |
| Total Liabilities | $291.8M | $173.2M | $176.6M | $184M | $192.5M | |
| Total Equity | $107.5M | $648.2M | $576.1M | $518M | $441.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.9M | -$50.7M | -$14.4M | -$6.8M | -$6.3M | |
| Cash From Investing | -$242.3M | -$33.6M | $57.9M | -$9.6M | -$13.1M | |
| Cash From Financing | $7.9M | -$1.6M | -$15.5M | -$1.2M | -$233K | |
| Free Cash Flow | -$86.7M | -$93.1M | -$68.8M | -$16.9M | -$19.3M | |
PL
Sector
Market Cap
$1B
$600.1M
Price % of 52-Week High
50.37%
72.84%
Dividend Yield
0%
0%
Shareholder Yield
--
2.42%
1-Year Price Total Return
32.55%
-7.65%
Beta (5-Year)
--
0.782
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.80
200-day SMA
Buy
Level
$3.20
Bollinger Bands (100)
Sell
Level
3.18 - 5.24
Chaikin Money Flow
Sell
Level
-58.3M
20-day SMA
Sell
Level
$3.98
Relative Strength Index (RSI14)
Sell
Level
33.31
ADX Line
Sell
Level
26.32
Williams %R
Buy
Level
-81.6065
50-day SMA
Sell
Level
$4.82
MACD (12, 26)
Sell
Level
-0.34
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
26.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1322)
Buy
CA Score
(Annual)
Level (-0.1041)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.5639)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.
Stock Forecast FAQ
In the current month, PL has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PL average analyst price target in the past 3 months is $6.03.
-
Where Will Planet Labs PBC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Planet Labs PBC share price will rise to $6.03 per share over the next 12 months.
-
What Do Analysts Say About Planet Labs PBC?
Analysts are divided on their view about Planet Labs PBC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Planet Labs PBC is a Sell and believe this share price will drop from its current level to $4.50.
-
What Is Planet Labs PBC's Price Target?
The price target for Planet Labs PBC over the next 1-year time period is forecast to be $6.03 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Planet Labs PBC is a Buy. 7 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PL?
You can purchase shares of Planet Labs PBC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Planet Labs PBC shares.
-
What Is The Planet Labs PBC Share Price Today?
Planet Labs PBC was last trading at $3.44 per share. This represents the most recent stock quote for Planet Labs PBC. Yesterday, Planet Labs PBC closed at $3.38 per share.
-
How To Buy Planet Labs PBC Stock Online?
In order to purchase Planet Labs PBC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 16.21% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 2.91% over the past day.
Sell
47
RGC alert for Apr 1
Regencell Bioscience Holdings [RGC] is down 3.23% over the past day.
